Editas Medicine (EDIT) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- US stock futures down as Middle East strikes fuel inflation anxiety
- Oil rises over 3% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
February 22, 2023 6:15 AM ESTCommenced parallel patient dosing in the EDIT-301 RUBY trial for SCD, following clinical proof-of-concept demonstrated last quarter
On track to provide clinical update for RUBY trial by mid-2023 and dose 20 total patients by year-end
On track to dose first patient in EDIT-301 EDITHAL trial for TDT in Q1 2023 and provide clinical update by year-end
Entered into definitive agreement to sell iNK cell franchise and out-license certain gene editing technologies to Shoreline Biosciences
CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Editas Medicine,... More
